Program
janagliflozin
Also written as “ganagliflozin”, “Janagliflozin plus metformin” and “Janagliflozin 25mg”.
Its studies are mostly in Diabetes Mellitus, Type 2, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Huadong Medicine | 22 open or running | phase 4since Jul 23, 2025 | Jul 23, 2025 | Dec 31, 2027phase 4 · NCT07244003 |
| Sihuan Pharmaceutical Holdings Group | 20 open or running | phase 3since Jan 17, 2019 | Jan 17, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 17, 2019First study: phase 3 study in Diabetes Mellitus, Type 2New to Sihuan Pharmaceutical Holdings GroupSihuan Pharmaceutical Holdings Group · NCT03811548 · 442 enrolled · China
- Feb 20, 2019Phase 3 study in Diabetes Mellitus, Type 2Sihuan Pharmaceutical Holdings Group · NCT03851432 · 390 enrolled · China
- Jul 23, 2025Huadong Medicine's first study: phase 4 study in Diabetes Mellitus, Type 2New to Huadong MedicineHuadong Medicine · NCT07116928 · 1,244 planned · China
- Nov 16, 2025Phase 4 study in Diabetes Mellitus, Type 2Huadong Medicine · NCT07244003 · 430 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 4 study in Diabetes Mellitus, Type 2Huadong Medicine · NCT07244003
- Oct 30, 2031Primary completion: phase 4 study in Diabetes Mellitus, Type 2Huadong Medicine · NCT07116928
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07244003Diabetes Mellitus, Type 2 · China | 4 | Recruiting | Huadong Medicine | Dec 31, 2027 | 430 |
| NCT07116928Diabetes Mellitus, Type 2 · China | 4 | Not yet recruiting | Huadong Medicine | Oct 30, 2031 | 1,244 |
| NCT03851432Diabetes Mellitus, Type 2 · China | 3 | UNKNOWN | Sihuan Pharmaceutical Holdings Group | Apr 30, 2020 | 390 |
| NCT03811548Diabetes Mellitus, Type 2 · China | 3 | UNKNOWN | Sihuan Pharmaceutical Holdings Group | Jun 24, 2020 | 442 |
How it is read
Names in the registry
- “ganagliflozin”, 2 entries
- “Janagliflozin plus metformin”, 2 entries
- “Janagliflozin 25mg”, 1 entry
- “Janagliflozin 50mg”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.